Unknown

Dataset Information

0

Reduction-rebridging strategy for the preparation of ADPN-based antibody-drug conjugates.

ABSTRACT: The reduction-rebridging strategy is a powerful method for the preparation of stable and homogeneous antibody-drug conjugates (ADCs). In this communication, we describe the development of the arylene-dipropiolonitrile (ADPN) functional group for the rebridging of reduced disulphide bonds and its application in the preparation of potent and selective ADCs.

SUBMITTER: Koniev O 

PROVIDER: S-EPMC6071946 | biostudies-literature |

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Investigating the Impact of Sample Preparation on Mass Spectrometry-Based Drug-To-Antibody Ratio Determination for Cysteine- and Lysine-Linked Antibody-Drug Conjugates.
| S-EPMC7551423 | biostudies-literature
Unknown Microtubule inhibitor-based antibody-drug conjugates for cancer therapy.
| S-EPMC4259504 | biostudies-other
Unknown Preparation and characterization of antibody-drug conjugates acting on HER2-positive cancer cells.
| S-EPMC7521679 | biostudies-literature
Unknown Monodisperse polysarcosine-based highly-loaded antibody-drug conjugates.
| S-EPMC6457330 | biostudies-literature
Unknown Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy.
| S-EPMC6152078 | biostudies-literature
Unknown Exatecan Antibody Drug Conjugates Based on a Hydrophilic Polysarcosine Drug-Linker Platform.
| S-EPMC8000490 | biostudies-literature
Unknown Harnessing a catalytic lysine residue for the one-step preparation of homogeneous antibody-drug conjugates.
| S-EPMC5653646 | biostudies-literature
Unknown DNA damaging agent-based antibody-drug conjugates for cancer therapy.
| S-EPMC6161754 | biostudies-literature
Unknown Preparation of well-defined antibody-drug conjugates through glycan remodeling and strain-promoted azide-alkyne cycloadditions.
| S-EPMC4128391 | biostudies-literature
Unknown Antibody-Drug Conjugates for Cancer Therapy.
| S-EPMC7587605 | biostudies-literature